RxDoctor Payments DataLook up a doctor →

Ernest Beasley, MD

Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1467562959

Payments from drug & device makers

$14,354in general payments, 2019–2025

Across 805 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Sanofi-aventis U.S. LLC$1K
  • IBSA Pharma Inc.$832
  • Tandem Diabetes Care, Inc.$620
  • plus $6K from 42 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk138$2,186
Lilly USA, LLC111$1,871
Amgen(2 entities)72$1,330
Sanofi-aventis U.S. LLC51$1,040
IBSA Pharma Inc.46$832
Tandem Diabetes Care, Inc.32$620
Abbott31$599
AbbVie41$584
Xeris Pharmaceuticals, Inc.27$539
Boehringer Ingelheim27$504
Corcept Therapeutics23$491
Amneal Pharmaceuticals LLC25$477
Dexcom, Inc.21$404
AstraZeneca(2 entities)22$354
Merck20$279
Johnson & Johnson20$250
Recordati_rare_diseases_inc.10$210
Bayer9$179
Valeritas, Inc.9$167
Ultragenyx Pharmaceutical Inc.6$128
Insulet Corporation6$121
Ipsen Biopharmaceuticals, Inc5$107
Astellas Pharma US Inc4$98
Kyowa Kirin, Inc.5$94
Cequr Corporation3$70
Shire North American Group Inc4$63
Neurocrine Biosciences, Inc.2$61
Medtronic(2 entities)3$54
Clarus Therapeutics Inc.3$54
Kowa Pharmaceuticals America, Inc.4$48
Amphastar Pharmaceuticals, Inc.2$46
Ascendis Pharma Endocrinology Inc2$45
Takeda Pharmaceuticals U.S.A., Inc.3$44
Intuity Medical Inc1$44
Mannkind Corporation2$42
Amryt Pharma Holdings Ltd2$38
Chiesi USA, Inc.2$35
Sequel Med Tech, LLC1$32
Madrigal Pharmaceuticals1$31
BETA Bionics, Inc.1$31
Averitas Pharma Inc.1$24
Alvogen Inc1$23
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$21
Endo Pharmaceuticals Inc.1$21
Dynavax Technologies Corporation1$20
Verity Pharmaceuticals Inc.1$18
EUSA Pharma (US) LLC1$14
GRT US Holding, Inc.1$14

How this compares

$14,354 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$163,265
Medicare patients
368
Services billed
3,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Atlanta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →